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A B S T R A C T   
Background: In multi-drug-resistant epilepsy vagus nerve stimulation (VNS) is an efficacious additional treatment 
to reduce seizure frequency and severity. A recently developed cardiac-based seizure detection (CBSD) algorithm 
triggers automate stimulation (AutoStim) upon heart rate increases of at least 20%. Yet, long term sensitivity and 
specificity of the CBSD-algorithm remain unclear. We present a case series of 15 adult patients with epilepsy with 
AutoStim VNS therapy. 
Methods: We reviewed CBSD-settings, operating hours and battery status of the devices. Percentage of AutoStim 
was assessed in comparison to continuous but intermittent stimulation. If seizure diaries were available, we 
verified whether a high rate of AutoStim was present during the documented seizures. 
Results: We reviewed 15 patients with a mean age of 34 years (±11y). Mean duration since implantation was 47 
months (±12 m). Of 1296 (±686) continuous intermittent stimulations per week, 4.8 (±3.9)% were AutoStim. 
Proportion of AutoStim varied substantially. While 9 patients had a mean of 1.5% (±1.4%), 6 patients had a 
significantly higher proportion of AutoStim 9.0% (±1.6%). Seizure-frequency was higher in patients with higher 
AutoStim frequency. Adverse events occurred in none of the patients. 
Conclusion: We provide long-term results for sensitivity and specificity of the CBSD algorithm. While sensitivity 
seems to be high, we presume specificity to be poor. An extremely high number of AutoStim is supposedly false- 
positive. Yet, treatment was well tolerated by the patients without any adverse events, despite the high number 
of AutoStim. CBSD is a promising development, yet the algorithm should be revised to provide a better 
specificity.   
1. Introduction 
According World Health Organisation (WHO) around 50 million 
people worldwide have epilepsy, making it one of the most common 
neurological diseases globally. Approximately 30% of patients remain 
multi-drug resistant. While 450.000–600.000 of those patients world-
wide might be suitable for epilepsy surgery, over 1.4millions remain 
candidates for other therapies such as VNS [1]. VNS was approved in the 
EU in 1994 for use as an adjunctive therapy in reducing the frequency of 
seizures in patients whose epileptic disorders are dominated by partial 
seizures (with or without secondary generalization) or generalized sei-
zures, which are refractory to anti-epileptic medications [2]. VNS 
therapy normalizes the inter-ictal EEG: Inter-ictal spikes, theta- 
synchronization, frequency and duration of spikes as well as spike-and 
wave activity are gradually reduced while the power spectrum, inter- 
hemispheric synchronization of the gamma band and the duration of 
spike-free intervals are increased [3–5]. Acute effects of VNS on elec-
trical ictal activity have driven the development of automated respon-
sive VNS therapy [6,7]. In 2014 a responsive VNS therapy was 
introduced that delivers automate stimulation (AutoStim) in response to 
a rapid heart rate increase that may be associated with seizures. 
AutoStim is delivered according a cardiac-based seizure detection 
(CBSD) algorithm. Therefore R-waves are identified and a baseline 
(background) heart rate according to R-R intervals of approximately 5 
min as well as near-term (foreground) heart rate for comparison is 
established. In case the foreground heart rate exceeds the background 
heart rate above a programmed threshold, a VNS train is automatically 
delivered [8]. 82% of patients with epilepsy experience rapid heart rate 
increase associated with a seizure, especially in terms of generalized 
tonic-clonic seizures [9–11], so heart rate increase is thought as a 
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biomarker of seizure activity. Ictal tachycardia occurs when hyper- 
excitation (seizure activity) affects brain regions, located in or directly 
connected to the mesial temporal lobe, responsible for autonomic con-
trol of cardiac rhythm [12]. Responsive VNS therapy combines open- 
loop-stimulation that delivers a long-term neuromodulatory effect in 
order to reduce seizure frequency and -severity and automatic stimu-
lation by CBSD in attempt to terminate seizures and reduce seizure 
propagation. The CBSD’s threshold of AutoStim is customizable to in-
dividual patients between 20 and 70% heart rate increase, thereby 
influencing detection latency. A prospective, unblinded study in patients 
with multi-drug-resistant partial onset seizures and history of ictal 
tachycardia has shown over 60% of seizures treated with automatic 
stimulation ended during stimulation [13]. Hamilton et al described an 
increased responder rate when patients switched from standard to 
automated stimulation [14]. Ravan et al showed that responsive VNS 
therapy reduces seizure duration by reducing generalization of focal 
onset seizures [15]. Automatic stimulation seems to improve therapy of 
multi-drug-resistant epilepsy. Yet, long term sensitivity and specificity 
of the CBSD-algorithm remain unclear. We present long term results of a 
case series of 15 adult patients with epilepsy with AutoStim VNS ther-
apy. Aim of our study is to figure out whether CBSD-algorithm which 
depends on the patient’s physiology in real time leads to a more suitable 
therapeutic value for each patient. 
2. Methods 
Patients were seen in the outpatient clinic or at their care facilities to 
review individual VNS data and seizure diaries. All patients had the 
same Closed-loop VNS device (Aspire SR ®, Liva Nova, Houston, Texas, 
USA)) implanted in our center. Open- and closed-loop VNS was active in 
all patients. We reviewed CBSD-settings, operating hours and battery 
status of the devices. Percentage of AutoStim was assessed in compari-
son to continuous but intermittent stimulation. If seizure diaries were 
available, we verified whether a high rate of AutoStim was present 
during the documented seizures. GraphPad Prism software was used for 
data analysis with Pearson correlation calculations and students t-test, 
alpha = 0.05. 
3. Results 
We reviewed 15 patients with a mean age of 34 years (±11y). Ten 
patients were men. Mean age at implantation of VNS therapy system was 
31 years (±11y). Mean duration since implantation was 47 months 
(±12 m). Mean operating time was 4276 h (1766–8907 h). CBSD 
thresholds ranged between 20% and 70% (20% in one, 30% in one, 40% 
in three, 50% in one, 60% in five and 70% in four patients). Stimulation 
pattern (per week) was: 1296 (±686) continuous intermittent stimula-
tions, 4.8 (±3.9)% AutoStim. Remaining battery life was 50–75%, 
consistently. Pearson correlation calculation showed no correlation be-
tween CBSD thresholds and percentage of AutoStim (r2 = 0.12, p = 0.2) 
(Fig. 1). Proportion of AutoStim varied substantially. According to 
seizure diaries and reports from patients and caregivers, patients had 
more AutoStim in case of higher seizure frequency (>5 seizures/week). 
One female patient with 1.88% AutoStim was seizure free since VNS, six 
patients with high proportion of AutoStim had > 5 seizures/week, two 
patients with 1.4% and 1.49% AutoStim reported > 5 seizures/week as 
well (Fig. 2A). Nevertheless, Pearson calculations showed no correlation 
between number of AutoStim and seizures per week (r2 = 0.1, p = 0.24) 
(Fig. 2B). 46.7% of the patients had an existing VNS replaced to an 
AutoStim VNS. Regarding seizure-frequency there was no difference 
between patients who received AutoStim VNS as their first model or had 
a replacement of a previous model. Neither was there a difference in 
percentage of AutoStim (3.43 vs 6.44%, p = 0.14, Fig. 3). 66.6% re-
ported an improvement following AutoStim VNS. Although three of 
those patients still experience > 5seizures/week severity of seizures 
were reduced. Four patients report no further generalized seizures 
following AutoStim VNS. Adverse events occurred in none of the 
patients. 
4. Discussion 
Our data provide long-term results of 15 patients who received CBSD 
AutoStim VNS. CBSD thresholds, proportion of AutoStim and seizure 
frequency varied substantially within a relatively small cohort. We 
chose >/< 5 seizures / week as surrogate parameter for meaningful 
clinical response because precise reports from seizure diaries were not 
available from the majority of patients. Furthermore, the relative long 
duration since VNS implantation impeded assessment of seizure fre-
quency reduction in comparison to patient’s situation before VNS 
treatment. In our data sensitivity of AutoStim VNS appears to be good 
since patients who report more seizures per week have a higher per-
centage of AutoStim although no correlation of seizure frequency and 
percentage of AutoStim was found (Fig. 2). Reports in which treatment 
of seizures with and without AutoStim were evaluated in epilepsy 
monitoring units (EMU) revealed good results. Beside a significant 
reduction of seizure duration, high sensitivity and specificity of 92% and 
13,5% respectively were described in a case report by Hampel et al[16]. 
In 2015 Boon et al published a prospective multicenter study (E-36 
Trial) including 31 patients one month after implantation of the VNS 
System. A very reliable correlation of seizures and AutoStim with a 
sensitivity of > 80% was found [17]. A parallel prospective multicenter 
study (E-37 Trial) with 20 patients was divided into an assessment on 
the EMU two–four weeks after device implantation and a follow-up 
period three, six and twelve months after implantation. During the 
EMU assessment 34.8% of detected seizures were treated with AutoStim 
on detection and 61.3% seizures ended during the stimulation. In the 
follow-up period the authors described an increasing responder rate, 
which they defined as > 50% seizure reduction, during the time of 
observation. 20% responder rate after three months developed to 50% 
after one year. Additionally a significant reduction of seizure severity 
and an improvement in quality of life was reported [13]. A main dif-
ference between our data and the afore mentioned studies is, that in 
contrast to data that was recorded during hospitalization, we provide 
long-term data based on reports of patients and caregivers. We found an 
extremely high number of stimulations despite relatively few seizures, 
which indicates specificity to be poor (Fig. 2B). An average of 53.9 
(±41.9) AutoStim / week appears inappropriate for significantly fewer 
reported seizures. Our assumption is supported by a case series in which 
three patients who were part of the E-36 Trial were described in further 
Fig. 1. Pearson correlation calculation showed no correlation between CBSD 
thresholds and percentage of AutoStim (r2 = 0.12, p = 0.2). Triangles indicate 
patients with > 5 seizures / week, squares indicate patients with < 5 seizures / 
week, circles indicate seizure free patients. 
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detail: On EMU CBSD AutoStim settings and seizures were recorded. 
Detection of ictal tachycardia was found to be successful but stimulation 
not strictly specific to ictal periods due to a high number of false- 
negative stimulations (mean 4.6 ± 0.96/h) [18]. In our data three pa-
tients mentioned an improvement in seizure severity even though 
seizure frequency wasn’t reduced. Four patients who experienced sec-
ondary generalization prior to AutoStim VNS had no generalized sei-
zures ever since. This observation matches an observation by Ravan et 
al, that seizures which were acutely stimulated using VNS had a reduced 
ictal spread [15]. Our data provide long-time consolidation of Kulju et al 
who found less energy consumption of VNS with AutoStim compared to 
previous models, since even some patients had a follow-up of more than 
five years since implantation, battery status was still > 75% charge [19]. 
A limitation of our study is, that compared to recordings of an EMU 
seizure detection might be underrepresented since it is completely based 
on reporting of patients and caregivers. Furthermore, the mismatch of 
lot AutoStim and much fewer detected seizures in our data could be 
explained by unnoticed seizures during sleep. In a short-term observa-
tion one month after VNS implantation Ravan et al. found reduced 
epileptiform activities during sleep [20]. In our data patients and care-
givers mentioned, that seizures that occur at night might not be detected 
and thus are not represented in seizure. 
5. Conclusion 
From our perspective sensitivity of closed loop VNS appears to be 
good since patients who report more seizures per week have a higher 
percentage of AutoStim. On the other hand, an extremely high number 
of AutoStim despite relatively few seizures indicates poor specificity. 
Yet, treatment is well tolerated by the patients without any adverse 
events. We found AutoStom to be a promising feature in the develop-
ment of a patient-tailored therapy but the CBSD algorithm should be 
revised to provide better specificity. 
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